Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 13/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022434 | 1.00 | AKR1C3 (0.55) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2024349 | 0.86 | AKR1C3 (0.40) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2024348 | 0.86 | AKR1C3 (0.40) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2026091 | 0.85 | AKR1C3 (0.42) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2026092 | 0.85 | AKR1C3 (0.42) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2025241 | 0.84 | HTR2A (0.37) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2025243 | 0.84 | HTR2A (0.37) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL12574527 | 0.83 | AKR1C3 (0.38) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2646494 | 0.83 | AKR1C3 (0.57) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2646492 | 0.83 | AKR1C3 (0.57) | AKR1C3PTGS2AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | AKR1C3 47/4885PTGS2 1562/4885AKR1C2 58/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | AKR1C3 47/4885PTGS2 1562/4885AKR1C2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.